Discussion of patient self reported adverse effects of Rituximab

Didn’t Mella even state that he thinks there is a subset that it works on?

I tend to agree with the stratification issue - ‘MECFS’ is ridiculously broad

Anyway, we will get more of an idea when the data is released & the individual case responses can be examined against the equivalent placebo (if there were, in fact, 3 year long responses)

 

I think Olav Mella may have been trying to let people down a bit lightly. My information is that the trial is negative. No useful information will come from comparing subsets post-hoc with results. Comparing individual responses to placebo tells us nothing, of course. We need to stick to science here. That is what Olav and Oystein would want.

 

Interesting that at the current Invest In ME conference, Professor Maureen Hanson emphasised the heterogeneity within groups.

 

@Dial It In I haven't seen any of the conference but did Professor Maureen Hanson speak about Rituximab specifically (or about an autoimmune sub-group or misdiagnosed group)? I am curious what she said (but am not on Twitter or other places where it might be posted).